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The National Health Service (NHS) Bowel Cancer Screening Programme (BCSP) in England uses a guaiac-based faecal occult blood test (gFOBt).  A quantitative faecal immunochemical test (FIT) for haemoglobin (Hb) has many advantages, including being specific for human blood, detecting Hb at a much lower concentration with a single faecal sample and improved uptake. 

Methods
In 2014 a large comparative pilot study was performed within BCSP to establish the acceptability and diagnostic performance of FIT. Over a 6-month period, 40,930 (1 in 28) subjects were sent a FIT (OC-SENSOR) instead of a gFOBt.  A bespoke FIT package was used to mail FIT sampling devices to and from FIT subjects.   All participants positive with either gFOBt or FIT  (cut-off 20 µg Hb/g faeces) were referred for follow-up. Subgroup analysis included cut-off concentrations, age, sex, screening history and deprivation quintile. 

Results
Whilst overall uptake increased by over 7 percentage points with FIT (66.4% vs. 59.3%, OR 1.35, 95% CI 1.33-1.38), uptake by previous non-responders almost doubled (FIT 23.9% vs. gFOBt 12.5%, OR 2.20 95% CI 2.10-2.29).  The increase in overall uptake was significantly higher in men than women, and was observed across all deprivation quintiles. With the conventional 20 µg/g cut-off, FIT positivity was 7.8% and ranged from 5.7% in 59-64 year-old women to 11.1% in 70-75 year-old men. Cancer detection increased 2-fold and that for advanced adenomas nearly 5‑fold. Detection rates remained higher with FIT for advanced adenomas, even at 180 µg Hb/g.

Conclusions






What is already known about this subject? 
	gFOBt screening for bowel cancer reduces bowel cancer mortality in those screened by 25%.
	Uptake of gFOBt in the NHS Bowel Cancer Screening Programme (BCSP) was 58.2% in the fiscal year 2014/5 and was lower in men, the deprived population and in previous non-responders.
	The faecal immunochemical test (FIT) for haemoglobin is recommended in the EU Guidelines on CRC Screening.
	FIT measures human haemoglobin and at lower concentrations than gFOBt.  Using an automated technique FIT provides a quantitative result that enables users to determine an acceptable positivity rate.
	Studies have shown increased uptake of FIT compared with gFOBt.
What are the new findings? 
	FIT can enable marked improvements in uptake and clinical outcomes in a well-established screening programme where subjects have received up to 7 previous invitations to screening.
	The adoption of an innovative package for mailing and returning the FIT device may have contributed to improved uptake.
	Uptake increased from 59.3% with gFOBt to 66.4% with FIT, an increase greater than has been reported previously in an established screening programme.
	The increase in uptake was greatest in previous in non-responders (FIT 23.9% vs. gFOBt 12.5%), and was higher in men than in women. This effect has not been reported previously.
	Uptake was increased across all deprivation quintiles (6.6 percentage points in the least deprived and 7.8 percentage points in the most deprived).
	FIT cut-off concentrations up to 40 μg Hb/g faeces achieved increased detection rates of cancer and up to 180 μg Hb/g faeces increased detection of advanced adenomas.
	.

How might it impact on clinical practice in the foreseeable future?
	Replacement of gFOBt with FIT in the NHS BCSP would result in a markedly increased uptake, particularly and importantly in some ‘hard-to-reach’ groups.
	The increase in uptake due to FIT has to be considered alongside FIT positivity when determining a cut-off concentration appropriate for the available colonoscopy resource.
	The design of packages used to distribute and return FIT devices should be considered by programme organisers.
	Data on the clinical effect of different cut-off concentrations in population subgroups will help maximise the clinical benefit within a prescribed colonoscopy resource in existing screening programmes. 
	Improved clinical outcomes can still be achieved at high cut-off concentrations.





Randomised controlled trials have shown that screening using a guaiac-based faecal occult blood test (gFOBt) can reduce mortality from bowel cancer  ADDIN EN.CITE ().  The NHS Bowel Cancer Screening Programme (BCSP) in England currently uses a gFOBt and invites men and women aged 60-74 (inclusive) for screening every two years. The Programme was rolled-out across England in 2006 and had achieved national coverage for 60-74 year-olds in 2015.  Whilst the uptake of gFOBt-based screening in the UK compares well with that in most other countries, it is low relative to the uptake amongst women in population-based breast or cervical screening programmes  ADDIN EN.CITE (, ). The uptake of gFOBt in England is higher in women than men, increases with age from 60 to 69 years and decreases with increasing levels of deprivation  ADDIN EN.CITE ().

Reported reasons for non-participation include low perceived relevance of screening and avoiding or delaying decision-making, but also having some degree of intention to take part but failing to do so because of practicalities  ADDIN EN.CITE (, , ). The gFOBt adopted by the NHS BCSP requires six faecal samples, two from each of three separate bowel motions, and the partially completed kit must be stored by the participant until all three bowel motions have been sampled. It is likely that the gFOBt sampling method and the screening algorithm used in England, whereby up to three gFOBt kits may be required to achieve a definitive screening test result  ADDIN EN.CITE (), are important deterrents to bowel cancer screening  ADDIN EN.CITE ().

An alternative faecal occult blood test, the ‘faecal immunochemical test’ (FIT) for haemoglobin (Hb) has many advantages including requiring a single faecal sample and being specific for human blood, which it can detect at much lower concentrations than is possible with gFOBt. The collection of the faecal sample is much simpler, using a stick that is re-inserted and hygienically sealed into a small tube containing a preservative buffer solution. The automated FIT analysers have the advantage of providing an objective quantitative faecal Hb concentration and enable colonoscopy referral to be based on a locally selected FIT cut-off concentration, whereas the determination of a positive gFOBt result is by subjective visual interpretation and has a single, manufacturer determined, cut-off concentration. FIT kits and the cost of mailing are, however, marginally more expensive than for gFOBt.

Many studies have shown higher uptake of FIT compared with gFOBt in average-risk populations  ADDIN EN.CITE (). FIT has been adopted for organised population-based screening in Italy, Slovenia, Australia, the Netherlands, France, Malta and Southern Ireland  ADDIN EN.CITE () and in February 2015 the Scottish government  announced plans to change from gFOBt to FIT screening ().

In 2014 the NHS BCSP performed a pilot study to examine the acceptability and diagnostic performance of using FIT in an established screening programme in England. The aims of the epidemiological evaluation of the pilot were to compare FIT and gFOBt in terms of uptake and the proportion of tests that are positive (positivity), both overall and within demographic subgroups, together with the uptake of colonoscopy in test-positive subjects, and detection rates and positive predictive values  (PPVs) for cancer, adenoma and advanced adenoma. As a pilot for a change to a national programme, the study also explored other practical issues pertinent to the adoption of FIT. The application of alow FIT cut-off concentration of 20 µg Hb/g faeces  with a relatively high positivity enabled assessment of the effect of a range of higher cut-off concentrations on screening outcomes, with positivity rates below and above that currently observed in the gFOBt-based programme.  

Methods 
The study used the routine screening population invited by either of two of the five English BCSP Hubs (the Midlands and North West and the Southern Hub). Each of these Hubs cover a large area of England and invites 1.1 – 1.2 million subjects for gFOBt screening each year.  The study population was therefore drawn from over half of the eligible population in England. Participants with positive FIT or gFOBt results were managed according to the usual BCSP protocol and given a clinic appointment for follow-up in their local Screening Centre (18 Centres in the Southern Hub, 15 Centres in the Midlands and North West Hub).  The sample size of the pilot was determined to provide 80% power to detect a difference between 60% and 62% uptake, at the 5% significance level in subgroups of the population by age and sex. 

The FIT system used for the Pilot was the OC-SENSOR sampling tube (3rd generation buffer) and OC-SENSOR Diana analyser (Eiken Chemical Co. Ltd., Japan, supplied by Mast Diagnostics, Bootle, UK) and the gFOBt was Hema-Screen (Immunostics Co., NJ, USA, supplied by Alpha Laboratories Ltd, Eastleigh UK). A sensitive FIT cut-off concentration of 20 µg Hb/g faeces (equivalent to 100 ng Hb/mL buffer with the OC-SENSOR sampling tube) was applied by the Hub laboratories to enable the pilot to explore the practical and clinical implications of applying a wide range of FIT screening sensitivities. To minimise the impact upon the colonoscopy workload of using a more sensitive test regime than that of gFOBt, the BCSP’s call/recall system was modified to ensure that only the 1st in every 28 routine invitations would be FIT. This regime was applied strictly to each Screening Centre throughout the period of the pilot. The order of invitations for each Centre is produced by the screening IT system (BCSS) and is not influenced by subject demographics. This protocol ensured that assignment to either a FIT or gFOBt invitation was not influenced by age, sex, screening history or  index of deprivation, making the assignment of subjects effectively random. All subjects are sent the routine pre-invitation letter eight days before being sent a test kit. The pre-invitation letters for gFOBt and FIT were similar in content; the gFOBt group received the usual gFOBt information leaflet () with the pre-invitation, whilst the FIT group received a version of the information leaflet appropriate for FIT with a single information sheet explaining that the individual had been invited as part of the FIT Pilot, and the rationale for study.  No subjects allocated to one test type were subsequently offered or allowed to transfer to the other test.






All data required for the epidemiological evaluation were recorded on the BCSS database.  Individual anonymised data for both FIT and gFOBt were provided to the Centre for Cancer Prevention, Queen Mary University of London (QMUL); this paper includes data recorded on the BCSS database as at early April 2015 (26 weeks after the last pilot screening invitation).

All subjects served by either of the two Hubs were included in the analysis. Age was defined as the subject’s age in years at the date of pre-invitation. Data were restricted to subjects aged 59-75 years, inclusive.  A few subjects (82) who were < 59 (n=45) or > 75 years-old (n=37) were excluded from the study (post invitation corrections to subject’s date of birth may account for these discrepancies).  Subjects aged 59 (n=7,352) or 75 years (n=83) were included because the date that pre-invitations were prepared and posted deviated by a few days from the birthday due to weekend birthdays and to routine measures designed to reduce random daily fluctuation in the rate of invitations. Uptake is reported by sex and age-group, by socio-economic status and by screening history (prevalent first-time invitees [mostly 60-year-old subjects], prevalent previous non-responders and incident [previous responders]).

Uptake was calculated as the proportion of subjects sent the pre-invitation letter that was ‘adequately’ screened. Subjects who are sent pre-invitations and then advise the programme that they do not wish to be screened are not excluded from the calculation. Adequate screening is defined by the BCSP as having either a definitive negative (normal) or definitive positive (abnormal) test result and the uptake calculation includes in the numerator only subjects returning a first kit within 182 days of pre-invitation. Subjects recorded as not having returned a first test kit or failing to reach a definitive test result by not returning a repeat kit following a weak positive, spoilt kit or technical error, are defined as having not been adequately screened. 

Positivity was calculated as the proportion of adequately screened subjects who had a definitive positive result. Colonoscopy uptake was calculated as the proportion of subjects with a positive test result who had a colonoscopy outcome/episode outcome recorded. (This included a small number of subjects who had an alternative diagnostic test such as flexible sigmoidoscopy or computerised tomographic (CT) colonography.)

Subjects with high-risk adenomas (>5 adenomas or >3 adenomas at least one of which was >1 cm) or intermediate-risk adenomas (3–4 small adenomas or at least one >1 cm) were defined as having advanced adenomas  ADDIN EN.CITE (). Detection rates were calculated using number of subjects adequately screened as the denominator and PPV calculations used the number of subjects with a definitive colonoscopy outcome as the denominator.

A composite indicator of area-based socio-economic deprivation for each subject according to their postcode of residence (Index of Multiple Deprivation [IMD]) was derived using the English Indices of Deprivation 2010 (). The indices use census-derived indicators of income, education, employment, environment, health and housing at small-area (lower layer super output areas [LSOA]) level to generate a scale from 0 (least deprived) to 83.33 (most deprived). IMD quintiles were based on the recorded IMD scores for all subjects invited by either Hub during the pilot study.   The IMD quintiles were Q1 :  0.61- 7.38;  Q2 : 7.39-11.77; Q3 : 11.78-17.41; Q 4 :  17.42-27.97; Q5 : 27.98- 83.33.  The IMD score was assigned and supplied by the Health and Social Care Information Centre (HSCIC) based on subject postcode of residence.

The Southern Hub and the Midlands and North West Hub have distinct demographic differences as evidenced by their IMD profile  ADDIN EN.CITE (), and the Midlands and North West Hub completed three rounds of biennial gFOBt screening of a small proportion of its population in a pilot programme prior to commencement of the National programme in July 2006 ADDIN EN.CITE (), meaning that subjects will have received up to seven previous invitation.










The overall uptake was 66.4% for FIT compared with 59.3% for gFOBt (OR 1.35, 95% Confidence Interval [CI] 1.33-1.38, p<0.001) (Table 2). Uptake of both FIT and gFOBt was slightly higher in the Southern Hub, but the increase from gFOBt to FIT was similar in both Hubs. A total of 2.15% FIT invitees (881/40,930) and 2.17% gFOBt invitees (24,431/1,126,087) requested not to receive a kit after the pre-invitation and before mailing the kit.

The most marked difference in uptake between FIT and gFOBt was seen in the prevalent (previous non-responder) episodes (FIT 23.9% vs. gFOBt 12.5%; OR 2.20, 95% CI 2.10-2.29) (Table 2). The prevalent first-time invitees also showed a marked increase (61.2% vs. 50.4%; OR 1.55, 95% CI 1.48-1.63) and in the ‘compliant’ population (those with incident episodes) uptake increased to 90.1% (90.1% vs. 85.8%; OR 1.50, 95% CI 1.43-1.57).

The increase in uptake was significantly greater in men (absolute difference 8.1% (FIT 64.5% vs. gFOBt 56.4%; OR 1.41, 95% CI 1.36-1.45)) than women (absolute difference 6.0% (68.1 % vs. 62.1; OR 1.31, 95% CI 1.27-1.34)) (Figure 2). The differential uptake between men and women was reduced from 5.7 percentage points with gFOBt to 3.6 percentage points with FIT.  In men aged 59-64 years there was an absolute difference of 10.6% (60.7% vs. 50.1%, OR 1.54 (95% CI 1.47-1.61), although that age-group has a large proportion of prevalent first-time invitees and the increase in uptake did not vary significantly by age group in the multivariate analysis (p value for interaction 0.22). 

Uptake with both FIT and gFOBt showed the expected inverse relationship with deprivation  ADDIN EN.CITE () (Figure 3). The increase in uptake with FIT versus gFOBt in IMD quintile 5 (most deprived) was 7.8 percentage points, 54.3% vs. 46.5%, (OR 1.37, 95% CI 1.31-1.43),and that in quintile 1 (least deprived) was 6.6 percentage points,73.5% vs. 66.9% (OR 1.37, 95% CI 1.30-1.44); the difference across quintiles was not significant. 






The overall positivity for FIT with a 20 μg Hb/g faeces cut-off concentration was 7.8%, and for gFOBt was 1.7% (OR 4.82, 95% CI 4.59-5.05) (Table 4a). The increased positivity of FIT compared with gFOBt was significantly higher in the Midlands and North West Hub (8.7% positive with FIT vs. 1.6% with gFOBt, OR 5.68, 95% CI 5.30-6.08) than in the Southern Hub (7.1% positive with FIT vs. 1.8% with gFOBt, OR 4.16, 95% CI 3.89-4.45); the positivity with gFOBt was higher in the Southern Hub.

Overall positivity for both FIT and gFOBt was highest in prevalent (previous non-responder) screening episodes (Table 4a). The increase in positivity with FIT was significant in all screening episodes, with the greatest increase observed in the incidence episodes (OR 5.06, 95% CI 4.79-5.35).
Positivity for both tests was higher in men than women, but the increase with FIT was similar (Table 4b). The increase in FIT positivity increased significantly with age, from an OR of 4.40 (95% CI 4.06-4.76) at 59-64 years to an OR of 5.21 (95% CI 4.76-5.70) at 70-75 years. Positivity increased with increasing level of deprivation, but the increase in positivity was similar across IMD quintiles (both overall and in the individual Hubs) (Table 4c). 

FIT positivity decreased steadily with increasing cut-off concentration, from 7.83% at 20 µg Hb/g faeces to 1.52% at 180 µg Hb/g faeces (Table 5a).  A similar pattern of reduced FIT positivity with increasing cut-off was evident for all screening episodes (Figure 4) and IMD quintiles (Figure 5). 









Using the cut-off concentration of 20 μg Hb/g the cancer detection rate was 0.27% with FIT compared with 0.12% for gFOBt (OR 2.20, 95% CI 1.73-2.79, p<0.001) (Table 5a). Detection rates of advanced adenoma were 1.73% with FIT and 0.35% with gFOBt (OR 4.97, 95% CI 4.50-5.49, p<0.001),. The detection rates  for all neoplasms including low risk adenomas were 3.74% and 0.76% respectively  (OR 5.05, 95% CI 4.72-5.41, p< 0.001) (data not shown). Rates of detection of both cancers and adenomas fell with increasing cut-off concentration. 

The cancer detection rate was no longer significantly higher with FIT at concentrations above 40 µg Hb/g faeces. At a concentration of 180 µg Hb/g faeces, the cancer detection rate was only slightly higher than that for gFOBt, but the detection rate of advanced adenomas remained  higher (0.43% vs. 0.35%, OR 1.21 (95%CI 1.00-1.46, p<0.05).

The detection rates of CRC and of advanced adenomas were more than twice as high in men as in women with both FIT at 20 µg Hb/g and gFOBt (Table 5a), but there was no significant difference in the increase with FIT between sexes. The increase in detection of advanced adenomas was highest in the oldest age group, and the Midlands and North West Hub (with higher positivity) had higher detection rates of advanced adenomas and all neoplasms than the Southern Hub (data not shown).
.

For advanced adenomas there was a significant difference in the increased detection with FIT between screening episode types at the cut-off concentration of 20 μg Hb/g.  The greatest increase was observed in incident screens where the detection of advanced adenomas increased from 0.33% to 1.71% (Table 5b) (OR 5.31, 95% CI 4.73-5.96, p<0.001). The detection of advanced adenomas fell more steeply with increasing cut-off concentration in subjects screened in the incident episode (Figure 6).





The PPV of FIT at 20 µg Hb/g for cancer was significantly lower than for gFOBt (4.0% vs. 8.3%, OR 0.47, 95% CI 0.37-0.60, p<0.001), but the PPVs for advanced adenoma were similar between tests (25.8% vs.24.0%, OR 1.10, 95% CI 0.98-1.23, p=0.1) (Table 5a), and for cancer plus advanced adenoma the PPV of FIT was non-significantly lower (OR 0.90 95% CI (0.82-1.01))For all neoplasms including low risk adenomas the PPV was higher for FIT; 55.6% vs 51.8% (OR 1.17, 95% CI 1.06-1.29, p=0.003) (data not shown).


The PPV of FIT for cancer increased with increasing cut-off concentration, from 4.0% to 10.6% (Table 5a); the PPV for advanced adenoma increased with increasing cut-off up to 100 µg Hb/g faeces, but not further.

Even after increasing the FIT cut-off concentration from 150 to 180 µg Hb/g to reduce positivity and allow for the increased uptake (ensuring similar colonoscopy requirements to that for gFOBt), FIT had a significantly higher detection rate and higher PPV for advanced adenomas and a higher PPV for all neoplasms than gFOBt (Table 5a).






The FIT pilot in England has demonstrated a significant and marked increase in uptake of the FIT kit compared with the gFOBt kit currently in use in the NHS BCSP. Organised population-based biennial colorectal cancer screening commenced in England in July 2006 and the screening device and screening algorithm have not changed since then. Whilst the national average uptake has gradually increased from 50.9% in 2006/7 to 58.2% in 2014/5, it remains poor when compared with the other NHS cancer screening programmes in spite of both local and national initiatives to improve it.  Uptake is poor at first invitation, particularly amongst men and amongst the deprived population, characterising the challenge that has faced the Programme since its inception. The FIT pilot provided an opportunity to begin to address these issues, and considerable efforts were made to make the invitation process, including presentation of test kit and instructions for use, as simple as possible. The resulting increase in uptake was larger than that obtained by most other intervention studies in established programmes  ADDIN EN.CITE (), perhaps reflecting these efforts. A study in Australia has reported a similar odds ratio for the effect of general practitioner endorsement on uptake, although with a lower baseline uptake of 32%(). Importantly, the differential uptake between men and women was reduced with FIT, with the absolute difference falling from 5.7% to 3.6%. Although we did not observe a significant decrease in the trend of decreasing uptake with increasing level of deprivation, an increase in uptake was observed across all quintiles of deprivation, with an absolute increase of nearly 8% in the most deprived quintile. Analysis using IMD quintiles based on the national distribution of scores, rather than those in the pilot population, did not alter our findings. Of particular importance is the marked increase in uptake observed in previous non-responders. The increase among first-time invitees is likely to be sustained in subsequent screening episodes, since numerous studies have shown that previous participation is a strong predictor of future compliance  ADDIN EN.CITE (, , ).

The increase in uptake reported here is greater than that observed in most studies elsewhere, although a meta-analysis of five studies found a risk ratio of 1.16 (95% CI 1.03-1.31) for compliance with FIT versus gFOBt (). The meta-analysis included one study () in which subjects were first required to collect the kit from a clinic; the proportion of subjects invited who collected a kit was lower in the FIT arm, but once the kits had been dispensed participation was higher with FIT.  The other four studies in the meta-analysis showed risk ratios for uptake with FIT ranging from 1.19 to 1.27  ADDIN EN.CITE (, , , ). Of these, the two largest studies, both in the Netherlands, which found uptake to increase from 46.9% or 49.5% with gFOBt to 59.6% or 61.5% with FIT, were both conducted in previously unscreened populations  ADDIN EN.CITE (, ).  A study in Scotland has reported overall uptake of 58.7% with FIT compared with 53.9% for gFOBt, with higher uptake in all age and deprivation quintiles for both men and women  ADDIN EN.CITE (, ).  However, in the Scottish study FIT uptake and clinical outcomes in two evaluation NHS Boards were compared with results obtained contemporaneously in two other similar NHS Boards and before and after the evaluation of FIT. The present study was conducted in the setting of a national population-based screening programme and, whilst it was not a formal randomised study, the selection of 1 in 28 subjects to receive a FIT, as described, led to a similar distribution of characteristics in the two groups of subjects, and thus to a more robust comparison than was possible in the study in Scotland. Our results show similar increases in uptake in the first screening episode to those reported in the Dutch studies.  Ours is the only study, however, to show a significant increase in uptake in previous non-responders, which has important implications for improving uptake overall. On the basis of these results the introduction of FIT in England would initially result in approximately 290,000 additional subjects being screened each year. As stated above, uptake is likely to continue to increase as those responding in the first screening episode continue to participate in later episodes. 

Differing demographics lead to regional variations in uptake and the introduction of FIT in the national programme is likely to result in greater increases in uptake (and colonoscopy workload) in some areas. The impact of FIT in the London region with its diverse population and current poor uptake  ADDIN EN.CITE () is particularly difficult to predict.  The use of a single cut-off concentration may result in different positivity in different Hubs due to differing demographic profiles; in the pilot study the increase in positivity with FIT differed between the two Hubs, but positivity increased across all IMD quintiles..

The detection of cancers and advanced adenomas was greatly increased with the relatively low FIT cut-off concentration used in the pilot, and the PPV for advanced adenoma was similar to that for gFOBt, even at this low cut-off.  In particular, it is noteworthy that the greatest increase in detection of advanced adenomas was seen in subjects previously screened. Detection rates of CRC and advanced adenomas (high- and intermediate-risk) fell with increasing FIT cut-off concentrations. The PPVs for cancer increased, but those for advanced adenomas did not alter greatly for cut-off concentrations above 100 μg Hb/g faeces. Other studies using the same cut-off of 20 μg Hb/g faeces have reported similar increases in cancer detection  ADDIN EN.CITE (, , ); the observed detection rates will vary according to population characteristics and, for advanced adenoma, with the definition used. 

An increase in uptake has implications for colonoscopy workload; the cut-off concentration for FIT used in the pilot was deliberately set at a low level to enable outcomes across a range of important cut-off concentrations to be studied. FIT positivity with this low cut-off was markedly higher than the current BCSP gFOBt positivity of about 1.7%. There is a relatively small resource of trained and accredited endoscopists in England; initially, it will be necessary to select a FIT cut-off concentration with a positivity (allowing for the marked increase in screening uptake), that delivers a colonoscopy referral rate similar to that currently experienced with gFOBt screening.  

In our study, using a FIT cut-off concentration of 180 µg Hb/g faeces, and allowing for the marked increase in uptake, the number of subjects referred to colonoscopy with a positive FIT would be similar to that with gFOBt, but would still result in a significantly higher detection rate and higher PPV for advanced adenomas and all neoplasms compared with gFOBt. It is likely that positivity at a fixed cut-off will fall with repeat screening as subjects with adenomas are removed from the population and this will provide the Programme with an opportunity to adjust the cut-off concentration and make the test more sensitive to the detection of neoplasia whilst maintaining the colonoscopy referral rate.

The use of different cut-off concentrations according to sex or other population characteristics (including screening history) has been proposed  ADDIN EN.CITE (, ). The determination of such cut-offs will vary according to whether the aim is to maximise detection rates, PPV or other outcomes. With the need to maintain a positivity similar to that of the current programme it is difficult to determine subgroup-specific cut-offs based on our data, but ongoing data collection should provide further information to enable such calculations.
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Screening episode	Prevalent (first-time invitees)	6,425	15.70%	174,723	15.52%
	Prevalent (previous non-responders)	11,858	28.97%	322,839	28.67%
































*subjects where postcode could not be linked to LSOA

Table 2 Uptake of FIT and gFOBt by Hub and screening episode


























Table 3  Results of multivariate analyses of  uptake and positivity
		Uptake	Positivity (at 20 µg/g)



















Table 4a Positivity of FIT (cut-off 20 µg Hb/g faeces) and gFOBt by screening episode and hub
										
 	 	Prevalent(first time invitees)	Prevalent(previous non-responders)	Incident(previous responders)	Total




























OR (total)	4.40 (4.06-4.76)	5.03 (4.64-5.45)	5.21 (4.76-5.70)	4.82 (4.59-5.05)











Table 4c Positivity of FIT (cut-off 20 µg Hb/g faeces) and gFOBt by IMD quintile
 	 	IMD1	IMD2	IMD3	IMD4	IMD5	n/k	Total

































Advanced Adenoma Detection Rate	2.40%	1.14%	1.73%	1.85%	0.79%	1.29%	0.98%	0.40%	0.67%	0.71%	0.29%	0.49%	0.62%	0.25%	0.43%	0.52%	0.21%	0.35%
Cancer PPV	5.01%	2.78%	4.00%	6.47%	3.94%	5.41%	9.69%	5.75%	8.06%	12.03%	6.92%	10.00%	12.62%	7.52%	10.62%	9.29%	7.05%	8.32%
Advanced Adenoma PPV	30.76%	19.85%	25.82%	34.10%	22.49%	29.20%	39.06%	25.66%	33.52%	37.76%	26.42%	33.25%	38.83%	27.07%	34.22%	28.84%	17.78%	24.04%
Odds ratios (FIT vs.gFOBt)) ( 95% CI)	All	All	All	All	All	All
Cancer detection	2.20 (1.73-2.79)	1.96 (1.52-2.52)	1.32 (0.98-1.79)	1.20 (0.88-1.65)	1.08 (0.77-1.51)	1.0
Advanced adenoma detection 	4.97 (4.50-5.49)	3.69 (3.29-4.13)	1.91 (1.64-2.22)	1.39 (1.16-1.65)	1.21 (1.00-1.46)	1.0
All neoplasm (cancer+advanced adenoma) detection	4.27 (3.89-4.68)	3.25 (2.93-3.60)	1.76 (1.54-2.02)	1.34 (1.15-1.46)	1.18 (1.00-1.38)	1.0
Cancer PPV	0.47 (0.37-0.60)	0.63 (0.49-0.82)	0.94 (0.69-1.29)	1.13 (0.81-1.57)	1.26 (0.89-1.78)	1.0
Advanced adenoma PPV 	1.10 (0.98-1.23)	1.28 (1.13-1.46)	1.50 (1.26-1.79)	1.39 (1.14-1.71)	1.52 (1.22-1.89)	1.0




Table 5b PPVs and detection rates by screening episode type, with different FIT cut-off concentrations (µg Hb/g faeces)

	FIT 20μg/g	FIT 40μg/g	FIT 100μg/g	FIT 150μg/g	FIT 180μg/g	gFOBt















































Figure 5 Positivity of FIT and gFOBt by IMD quintile using varying FIT cut-off concentrations (µg Hb/g faeces)
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